Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T70849 |
AZD-4121
|
||
AZD-4121 is an oral cholesterol absorption inhibitor targeting NPC1L1 for the treatment of dyslipidaemia. | |||
T70848 |
AZD-4121 tert-butylammonium
|
||
AZD-4121 tert-butylammonium is an oral cholesterol absorption inhibitor targeting NPC1L1 for the treatment of dyslipidaemia. | |||
T70847 |
BMS-351
|
||
BMS-351 is a potent and selective, nonsteroidal CYP17A1 lyase inhibitor with robust selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 emerges as an outstanding preclinical candidate to treat CRPC and is likely to minimize the side effects of current therapies due to its exceptional selectivity. BMS-351 is potentially useful for the Treatment of Prostate Cancer. | |||
T70846 |
Deleobuvir sodium
|
||
Deleobuvir sodium is the salt form of Deleobuvir, also known as BI207127, a non-nucleoside hepatitis C virus NS5B polymerase inhibitor for the treatment of hepatitis C. Deleobuvir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including faldaprevir. Deleobuvir showed that a triple combination of deleobuvir, faldaprevir, and ribavirin performed well in HCV genotype 1b patients. Efficacy fell b... |